Regulators and academics paving new paths for  clinical cancer research

IBCD 2020 will explore routes through the constantly evolving scientific, methodological and regulatory environment for drug and biomarker development. The EORTC, NCI, EMA, and AACR with the involvement of FDA and PMDA and Health Technology Assessment specialists endeavour to build upon the recommendations and action points decided upon at the IBCD2018 edition.

Programme

The programme will address topics such as Health Technology Assessment (HTA) of biomarker assays, comparative effectiveness research and the translation of findings of clinical trials into daily practice . The conference will also discuss and debate the emergence of new regulatory routes to approve new anti-cancer agents based on biomarkers, demonstrating the relevance and feasibility of innovative clinical trial designs.

Read more
Programme - Illustration

Registration

Would you like to participate in IBCD?

REGISTER FOR FREE
Sponsorship -illustration

Sponsorship

We welcome your support for this meeting which will foster new forms of partnerships between academia, industry, regulatory, health technology assessment bodies and payers adding value to tomorrow’s personalised cancer treatments for patients in a daily practice setting.

Scientific Committee

Roberto Salgado - EORTC

Robert Salgado, Belgium
Chair

EORTC

Luc Dirix - EORTC

Luc Dirix, Belgium

Elisa Giovannetti - EORTC

Elisa Giovanetti, Italy

NCI

Tracy Lively - NCI

Tracy Lively, USA,
Cochair

Sherry X. Yang - NCI

Sherry Yang, USA

EMA

Sinan B Sarac - EMA

Sinan B. Sarac, Netherlands,
Cochair

Jonas Bergh - EMA

Jonas Bergh, Sweden

AACR

David Solit - AACR

David Solit, USA,
Cochair

Kurt Schalper - AACR

Kurt Schalper, USA